Kinetic Analysis of the Interaction between Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Using Wavelength Modulation Surface Plasmon Resonance

被引:0
|
作者
Liu Xia [1 ]
Li Ying [1 ]
Lin Zhao [1 ]
机构
[1] Hunan Agr Univ, Coll Food Sci & Technol, Hunan Prov Key Lab Food Sci & Biotechnol, Changsha 410128, Hunan, Peoples R China
基金
国家高技术研究发展计划(863计划);
关键词
surface plasmon resonance; biosensor; cyclooxygenase; drug; affinity; BIOSENSOR; PREDICTION; BOVINE;
D O I
10.1002/cjoc.201190046
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
A surface plasmon resonance (SPR) biosensor based on wavelength modulation technology was developed and validated for the kinetic analysis of the interactions between two nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX-2). After the effect of different concentration COX-2 on the binding capacity of the SPR biosensor surface was studied, the COX-2 was immobilized covalently onto the biosensor surface using a standard amine coupling method. The affinity constants for indomethacin, ketoprofen binding to COX-2 are 7.5 X 10(3) L/mol and 9.25X10(3) L/mol, respectively. The biosensor surface can be regenerated after being rinsed with 0.01 mol/L NaOH, and the biosensor can be used repeatedly. These indicated that the wavelength modulation SPR biosensor has the potential application in the fields of pharmacokinetics, pharmacodynamics and drug discovery.
引用
收藏
页码:165 / 170
页数:6
相关论文
共 50 条
  • [41] Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease
    Hennekens, Charles H.
    Borzak, Steven
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2008, 13 (01) : 41 - 50
  • [42] Increased cyclooxygenase-2 expression in human squamous cell carcinomas of the head and neck and inhibition of proliferation by nonsteroidal anti-inflammatory drugs
    Lee, DW
    Sung, MW
    Park, SW
    Seong, WJ
    Roh, JL
    Park, B
    Heo, DS
    Kim, KH
    ANTICANCER RESEARCH, 2002, 22 (04) : 2089 - 2096
  • [43] Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?
    Feldman, M
    McMahon, AT
    ANNALS OF INTERNAL MEDICINE, 2000, 132 (02) : 134 - 143
  • [44] Analysis of Nonsteroidal Anti-inflammatory Drugs by using Microfluidic Techniques: A Review
    Fanali, Chiara
    D'Orazio, Giovanni
    Gentili, Alessandra
    Fanali, Salvatore
    CURRENT PHARMACEUTICAL ANALYSIS, 2021, 17 (03) : 303 - 315
  • [45] Prevention of Peridural Fibrosis Using a Cyclooxygenase-2 Inhibitor (Nonsteroidal Anti-inflammatory Drug) Soaked in Absorbable Gelatin Sponge
    Sae-Jung, Surachai
    Jirarattanaphochai, Kitti
    SPINE, 2013, 38 (16) : E985 - E991
  • [46] Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process
    Vuolteenaho, Katriina
    Moilanen, Teemu
    Moilanen, Eeva
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2008, 102 (01) : 10 - 14
  • [47] Cyclooxygenase type-2 selective nonsteroidal anti-inflammatory drugs for inhibition of preterm labor
    Slater, DM
    Sawdy, R
    Dennes, WJB
    Allport, V
    Bennett, PR
    FOURTH INTERNATIONAL CONGRESS ON ESSENTIAL FATTY ACIDS AND EICOSANOIDS, 1998, : 64 - 67
  • [48] Cyclooxygenase-2, a colorectal cancer nonsteroidal anti-inflammatory drug target, is regulated by c-MYB
    Ramsay, RG
    Friend, A
    Vizantios, Y
    Freeman, R
    Sicurella, C
    Hammett, F
    Armes, J
    Venter, D
    CANCER RESEARCH, 2000, 60 (07) : 1805 - 1809
  • [49] Socioeconomic and pharmacoepidemiologic data on cyclooxygenase-2 (COX-2) selective anti-inflammatory drugs
    Ruof, J
    Hülsemann, JL
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2000, 59 (02): : 124 - 127
  • [50] Renal effects of selective cyclooxygenase-2 inhibitor anti-inflammatory drugs: A systematic review and meta-analysis
    Biase, Tayanny Margarida Menezes Almeida
    Rocha, Joao Gabriel Mendes
    Silva, Marcus Tolentino
    Ribeiro-Vaz, Ines
    Galvao, Tais Freire
    EXPLORATORY RESEARCH IN CLINICAL AND SOCIAL PHARMACY, 2024, 15